Global Anemia in Chronic Kidney Disease Market and Forecast Analysis 2018-2035: The Launch of Novel HIF Inhibitor Roxadustat will Offset Biosimilar Erosion of Epogen to Drive Market Growth
Chronic kidney disease (CKD) is characterized by decreased kidney function and kidney damage. Damaged renal tissue has a diminished ability to produce erythropoietin, a hormone that stimulates red blood cell production. Consequently, patients with CKD often experience anemia, defined as a reduction in red blood cells or hemoglobin levels. The risk of anemia increases as CKD progresses and kidney function declines.
Market Snapshot
The launch of novel HIF inhibitor roxadustat will offset biosimilar erosion of Epogen to drive market growth.
Physicians expect to switch a significant portion of patients on stable erythropoiesis-stimulating agent (ESA) therapy to oral ESAs within three years of their launch.
Between 2015 and 2035, the number of prevalent cases of anemia in chronic kidney disease (CKD) is forecasted to increase from 11.3 million to 14.9 million. This is due to a forecasted increase in the number of prevalent CKD cases, which is driven by population growth and aging, although increasing diabetes prevalence will also play a major role in shaping the future prevalence of anemia in CKD.
Use of erythropoiesis-stimulating agents, the standard of care for anemia in CKD, may decline due to cost and safety concerns.
Pipeline therapies plan to capture market share by reducing costs and safety concerns associated with treatment.
Bristol Myers Squibb today announced the Phase 3 CheckMate -73L trial did not meet its primary endpoint of progression-free survival (PFS) in unresectable, locally advanced stage III non-small cell lung cancer (NSCLC). CheckMate -73L evaluated...
Gossamer Bio, Inc. , a clinical-stage biopharmaceutical company focused on the development and commercialization of seralutinib for the treatment of pulmonary arterial hypertension (PAH) and pulmonary hypertension associated with interstitial lung...
Merrimack Pharmaceuticals, Inc. ("Merrimack" or the "Company") announced that the stockholders at a Special Meeting held today overwhelmingly approved adopting a Plan of Dissolution. Following that announcement, the Board of Directors declared a...
The Honourable Jean-Yves Duclos, MP for Québec and Minister of Public Services and Procurement, on behalf of the Honourable Mark Holland, Minister of Health, and the Honourable Carla Qualtrough, Minister of Sport and Physical Activity, will announce...
Chemistree Technology Inc. and (the "Company" or "Chemistree"), announces that is has completed the previously announced restructuring transaction (the "Restructuring Transaction") to settle $6,668,000 in principal amount of outstanding 10% senior...
Edesa Biotech, Inc. , a clinical-stage biopharmaceutical company focused on developing host-directed therapeutics for immuno-inflammatory diseases, today reported financial results for the three and six months ended March 31, 2024 and provided an...